DHX38 and ovarian clear cell cancer: By employing a CRISPR‐Cas9 screen, we uncovered DHX38/PRP16 as a novel genetic vulnerability whose knockdown results in growth suppression of ovarian clear cell carcinoma both in vitro and in vivo.